AURORA MELLIJOR-SOLIGUEN: Open Payments
NPI 1417978537 · UPLAND, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,042 in 42 payments from 10 companies in 2025. Trend: 2023 $764 · 2024 $660 · 2025 $1,042
Food & beverage: $1,042
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 7 | $291 |
| ABBVIE INC. | 8 | $179 |
| Axsome Therapeutics, Inc. | 8 | $147 |
| Otsuka America Pharmaceutical, Inc. | 5 | $140 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $110 |
| Almatica Pharma LLC | 3 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $45 |
| E.R. Squibb & Sons, L.L.C. | 1 | $29 |
| Janssen Pharmaceuticals, Inc | 1 | $26 |
| TMS NeuroHealth Centers Inc. | 1 | $19 |
Products named: VRAYLAR, ARISTADA, Auvelity, REXULTI, LYBALVI, CAPLYTA, LOREEV XR, TRINTELLIX.
Industry payments across CA — which companies pay providers there.
